Your thoughts here were so insightful that I couldn't find them, due to first searching only through posts made by Sales.
:-)
Nonetheless, when YOU were kind enough to drop in and pull out crystal ball? My thought was....... OK, well, if the jak2 corporate line went poof in favor of jak1 selectivity, how about jak3?
As you'll already know, Vertex issued a release with 12 week results, late breaker for ACR. Efficacy is very good. Hint of side effects, too early/few patients to get a clear view.
finance.yahoo.com
this high level of selectivity was confirmed in clinical studies where dose-related inhibition of a JAK3-dependent biomarker was observed while little to no effect was shown against a JAK2/JAK1-dependent biomarker
Meanwhile.... Lilly continues to launch drug interaction trials.
Switching disease, does anyone know when GILD plans to launch its phase III program with ex-cyt387? And I'm certain that everyone saw/knew about this, but it didn't make the thread.....
celltherapeutics.com
Best of luck, all.
Rick
|
